아시아태평양의 항체약물접합체 시장 : 지역별 분석 - 기술별, 용도별, 유통 채널별, 예측(-2030년)

The Asia Pacific antibody drug conjugates market was valued at US$ 1,532.83 million in 2022 and is expected to reach US$ 6,971.03 million by 2030; it is estimated to grow at a CAGR of 20.8% from 2022 to 2030.

Rising Need for AI in Consent Management Fuels the Asia Pacific Antibody Drug Conjugates Market

Rising cancer incidences are primarily leading to the increasing demand for innovative cancer treatments. As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, there were 19.3 million cancer cases across the globe. China, and India were among the countries leading in cancer cases. The GLOBOCAN has also estimated that the cancer cases in India will be ~2.08 million by 2040, representing a rise of 57.5% from 2020. Similarly, as per the World Health Organization (WHO) data published in February 2022, ~10 million people have died from cancer. The most commonly seen cancer types were lung, breast, colon and rectum, prostate, and breast. The rising incidences of cancer have raised concerns worldwide. Below is the list of common cancer cases reported worldwide in 2020.

• Table 1. New Cancer Cases Worldwide, in 2020

Sr. No. Cancer Type Number of Cases (Million)

1 Stomach 1.09

2 Skin (non-melanoma) 1.2

3 Prostate 1.41

4 Colon and Rectum 1.93

5 Lung 2.21

6 Breast 2.26

Cancer is now a lifestyle disease commonly seen among people with unhealthy food habits and who are physically inactive. Also, the consumption of alcohol and tobacco adds up to the risk of developing cancer. Chronic infectious diseases in low- and middle-income countries can further aggravate the cancer risk factors. According to the WHO data published in February 2022, chronic infectious diseases such as human papillomavirus (HPV), Helicobacter pylori, hepatitis B virus, hepatitis C virus, and Epstein-Barr virus attributed to nearly 18% of the diagnosed in 2018. Also, promising results of ADCs are anticipated to accelerate their demand as an effective cancer treatment and propel the market growth.

Asia Pacific Antibody Drug Conjugates Market Overview

The Asia Pacific antibody drug conjugates (ADCs) market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The growth of the ADCs market is widely driven by company collaborations, growing incidences of cancer, and increasing clinical trials.

The leading companies in Asia Pacific countries that are involved in developing ADCs have pipeline products to be launched in the market after completing the clinical trials. In June 2023, RemeGen Co., Ltd. signed an agreement with Innovent Biologics, Inc. to enter clinical trials and supply combination therapies TYVYT (sintilimab injection) with RC88, a novel mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), or TYVYT with RC108, a novel c-Met-targeting ADC. These are claimed to be novel therapies to treat solid tumors. Under the agreement, RemeGen Co., Ltd will conduct Phase 1/2a clinical studies for TYVYT to evaluate the anti-tumor activity and safety. The company also has Distamab vedotin (RC48) +PD1 combination in the pipeline. The combination is evaluated in two phases for different cancer indications, first combination is in phase III, evaluated to treat urothelial cancer in and second is in phase II, evaluated to treat muscle invasive bladder and gastric cancer.

In addition, Japanese companies are introducing breakthrough products that are expected to dominate the ADCs market. In June 2021, Daiichi Sankyo Company, Limited, and AstraZeneca plc launched Enhertu-a novel class of ADCs developed to treat HER2-low breast cancer patients. Daiichi Sankyo Company, Limited reported a year-on-year sales growth of 156.6% in the first quarter of 2023 by combining the US and European sales. Such a huge growth in the company's sales has significantly contributed to the ADCs market size in the country and is estimated to grow exponentially in the coming years.

Asia Pacific Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Antibody Drug Conjugates Market Segmentation

The Asia Pacific antibody drug conjugates market is segmented based on technology, application, distribution channel, and country.

Based on technology, the Asia Pacific antibody drug conjugates market antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held a larger share in 2022.

Based on application, the Asia Pacific antibody drug conjugates market antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held the largest share in 2022.

Based on distribution channel, the Asia Pacific antibody drug conjugates market antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share in 2022.

Based on country, the Asia Pacific antibody drug conjugates market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Japan dominated the Asia Pacific antibody drug conjugates market in 2022.

Pfizer Inc, Hoffmann-La Roche Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd are some of the leading companies operating in the Asia Pacific antibody drug conjugates market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Market Attractiveness

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Asia Pacific Antibody Drug Conjugates Market - Key Industry Dynamics

• 4.1 Key Market Drivers:
  • 4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
  • 4.1.2 Rising Incidences of Cancer Cases
  • 4.1.3 Increasing FDA Approvals for ADCs
• 4.2 Market Restraints
  • 4.2.1 High Cost of ADCs Development and Commercialization
• 4.3 Market Opportunities
  • 4.3.1 Increasing Investments to Develop ADCs
• 4.4 Market Trends
  • 4.4.1 Escalating Pipeline of ADCs
• 4.5 Impact Analysis:

5. Antibody Drug Conjugates Market - Asia Pacific Market Analysis

• 5.1 Asia Pacific Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030

6. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Technology

• 6.1 Overview
• 6.2 Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
• 6.3 Cleavable Linker
  • 6.3.1 Overview
  • 6.3.2 Cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
• 6.4 Non-cleavable Linker
  • 6.4.1 Overview
  • 6.4.2 Non-cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Application

• 7.1 Overview
• 7.2 Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
• 7.3 Blood Cancer
  • 7.3.1 Overview
  • 7.3.2 Blood Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 Breast Cancer
  • 7.4.1 Overview
  • 7.4.2 Breast Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
• 7.5 Ovarian Cancer
  • 7.5.1 Overview
  • 7.5.2 Ovarian Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
• 7.6 Urothelial Cancer
  • 7.6.1 Overview
  • 7.6.2 Urothelial Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
• 7.7 Others
  • 7.7.1 Overview
  • 7.7.2 Others: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Distribution Channel

• 8.1 Overview
• 8.2 Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
• 8.3 Hospital Pharmacies
  • 8.3.1 Overview
  • 8.3.2 Hospital Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
• 8.4 Retail Pharmacies
  • 8.4.1 Overview
  • 8.4.2 Retail Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
• 8.5 Online Pharmacies
  • 8.5.1 Overview
  • 8.5.2 Online Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Antibody Drug Conjugates Market - Country Analysis

• 9.1 Asia Pacific Antibody Drug Conjugates Market, Revenue and Forecast To 2030
  • 9.1.1 Overview
  • 9.1.2 Asia Pacific Antibody Drug Conjugates Market Breakdown, by key Country - Revenue (2022) (US$ Million)
  • 9.1.3 Asia Pacific: Antibody Drug Conjugates Market, by Country
    • 9.1.3.1 China
      • 9.1.3.1.1 Overview
      • 9.1.3.1.2 China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.3.1.3 China: Antibody Drug Conjugates Market, by Technology
      • 9.1.3.1.4 China: Antibody Drug Conjugates Market, by Application
      • 9.1.3.1.5 China: Antibody Drug Conjugates Market, by Distribution Channel
    • 9.1.3.2 Japan
      • 9.1.3.2.1 Overview
      • 9.1.3.2.2 Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.3.2.3 Japan: Antibody Drug Conjugates Market, by Technology
      • 9.1.3.2.4 Japan: Antibody Drug Conjugates Market, by Application
      • 9.1.3.2.5 Japan: Antibody Drug Conjugates Market, by Distribution Channel
    • 9.1.3.3 India
      • 9.1.3.3.1 Overview
      • 9.1.3.3.2 India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.3.3.3 India: Antibody Drug Conjugates Market, by Technology
      • 9.1.3.3.4 India: Antibody Drug Conjugates Market, by Application
      • 9.1.3.3.5 India: Antibody Drug Conjugates Market, by Distribution Channel
    • 9.1.3.4 South Korea
      • 9.1.3.4.1 Overview
      • 9.1.3.4.2 South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.3.4.3 South Korea: Antibody Drug Conjugates Market, by Technology
      • 9.1.3.4.4 South Korea: Antibody Drug Conjugates Market, by Application
      • 9.1.3.4.5 South Korea: Antibody Drug Conjugates Market, by Distribution Channel
    • 9.1.3.5 Australia
      • 9.1.3.5.1 Overview
      • 9.1.3.5.2 Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.3.5.3 Australia: Antibody Drug Conjugates Market, by Technology
      • 9.1.3.5.4 Australia: Antibody Drug Conjugates Market, by Application
      • 9.1.3.5.5 Australia: Antibody Drug Conjugates Market, by Distribution Channel
    • 9.1.3.6 Rest of Asia Pacific
      • 9.1.3.6.1 Overview
      • 9.1.3.6.2 Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
      • 9.1.3.6.3 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Technology
      • 9.1.3.6.4 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Application
      • 9.1.3.6.5 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Distribution Channel

10. Asia Pacific Antibody Drug Conjugates Market-Industry Landscape

• 10.1 Overview
• 10.2 Organic Growth Strategies
  • 10.2.1 Overview
• 10.3 Inorganic Growth Strategies
  • 10.3.1 Overview
• 10.4 Companies' Manufacturing Capacities and Capabilities

11. Company Profiles

• 11.1 Pfizer Inc
  • 11.1.1 Key Facts
  • 11.1.2 Business Description
  • 11.1.3 Products and Services
  • 11.1.4 Financial Overview
  • 11.1.5 SWOT Analysis
  • 11.1.6 Key Developments
• 11.2 Hoffmann-La Roche Ltd
  • 11.2.1 Key Facts
  • 11.2.2 Business Description
  • 11.2.3 Products and Services
  • 11.2.4 Financial Overview
  • 11.2.5 SWOT Analysis
  • 11.2.6 Key Developments
• 11.3 GSK Plc
  • 11.3.1 Key Facts
  • 11.3.2 Business Description
  • 11.3.3 Products and Services
  • 11.3.4 Financial Overview
  • 11.3.5 SWOT Analysis
  • 11.3.6 Key Developments
• 11.4 Gilead Sciences Inc
  • 11.4.1 Key Facts
  • 11.4.2 Business Description
  • 11.4.3 Products and Services
  • 11.4.4 Financial Overview
  • 11.4.5 SWOT Analysis
  • 11.4.6 Key Developments
• 11.5 AstraZeneca Plc
  • 11.5.1 Key Facts
  • 11.5.2 Business Description
  • 11.5.3 Products and Services
  • 11.5.4 Financial Overview
  • 11.5.5 SWOT Analysis
  • 11.5.6 Key Developments
• 11.6 Astellas Pharma Inc
  • 11.6.1 Key Facts
  • 11.6.2 Business Description
  • 11.6.3 Products and Services
  • 11.6.4 Financial Overview
  • 11.6.5 SWOT Analysis
  • 11.6.6 Key Developments
• 11.7 RemeGen Co Ltd
  • 11.7.1 Key Facts
  • 11.7.2 Business Description
  • 11.7.3 Products and Services
  • 11.7.4 Financial Overview
  • 11.7.5 SWOT Analysis
  • 11.7.6 Key Developments
• 11.8 Takeda Pharmaceutical Co Ltd
  • 11.8.1 Key Facts
  • 11.8.2 Business Description
  • 11.8.3 Products and Services
  • 11.8.4 Financial Overview
  • 11.8.5 SWOT Analysis
  • 11.8.6 Key Developments

12. Appendix

• 12.1 About Us
• 12.2 Glossary of Terms